Sight Sciences Reports Third Quarter 2021 Financial Results
MENLO PARK, Calif., November 10, 2021 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today reported financial results for the quarter ended September 30, 2021.
Recent Business Highlights
- Generated record third quarter 2021 total revenue of $13.1 million, an increase of 51% compared to the prior year period
- Expanded gross margin to 84% in the third quarter 2021 versus 70% in the prior year period
- Received FDA Investigational Device Exemption (IDE) approval for PRECISION, a three-armed combination cataract MIGS randomized controlled trial (RCT) to assess the safety and effectiveness of canaloplasty-alone procedures using the OMNI® Surgical System
- Submitted 510(k)…